Ibutamoren (MK-677): Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข3 clinical studies cited
- โขOverall evidence level: moderate
- โข5 research gaps identified
Research Studies
Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial
Nass R, Pezzoli SS, Oliveri MC, et al. (2008) โข Annals of Internal Medicine
Landmark 2-year modified crossover RCT in 65 healthy adults aged 60-81. MK-677 25 mg daily significantly increased fat-free mass by 1.6 kg over 12 months and restored GH and IGF-1 levels to those of young adults.
Key Findings
- Fat-free mass increased 1.1 kg with MK-677 vs decrease of 0.5 kg with placebo (P<0.001, between-group difference 1.6 kg)
- GH secretion increased by approximately 97% compared to baseline
- IGF-1 levels increased to ranges typical of healthy young adults
- No significant change in total fat mass or visceral fat
- Fasting glucose increased by approximately 0.3 mmol/L with MK-677
Limitations: Relatively small sample size (n=65); predominantly healthy elderly population may not generalize to frail or diseased populations; did not assess functional outcomes such as strength or physical performance
MK-0677 (Ibutamoren Mesylate) for the Treatment of Patients Recovering from Hip Fracture: A Multicenter, Randomized, Placebo-Controlled Phase IIb Study
Adunsky A, Chandler J, Heyden N, et al. (2011) โข Archives of Gerontology and Geriatrics
Phase 2b trial of MK-677 25 mg daily in 123 elderly patients recovering from hip fracture. Study was terminated early at 24 weeks due to higher rates of congestive heart failure in the ibutamoren group.
Key Findings
- Congestive heart failure rate: 6.5% ibutamoren vs 1.7% placebo
- Trial stopped early due to CHF safety signal
- GH and IGF-1 levels were increased as expected
- No significant improvement in functional recovery endpoints at time of termination
Limitations: Terminated early, limiting efficacy assessment; elderly hip fracture patients represent a high-risk cardiac population; small sample size limits statistical power for safety conclusions
The Effects of MK-0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture
Bach MA, Rockwood K, Zetterberg C, et al. (2004) โข Journal of the American Geriatrics Society
Earlier hip fracture trial in elderly patients. MK-677 suggested improvements in some functional measures and muscle strength, though the study was not designed to assess cardiac safety.
Key Findings
- Suggested improvement in muscle strength measures
- Improvement in some functional performance measures
- GH/IGF-1 axis activation confirmed
- Treatment was generally well tolerated in this trial
Limitations: Smaller trial; did not specifically monitor for CHF as a primary safety endpoint; findings not replicated in the subsequent larger trial
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 300+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขLong-term cardiovascular safety in elderly and at-risk populations remains poorly characterized
- โขNo large-scale trials evaluating functional outcomes (strength, mobility, fall prevention) have been completed
- โขEffects on bone mineral density and fracture risk require larger, longer-term studies
- โขThe relationship between GH/IGF-1 elevation and potential cancer promotion has not been adequately studied with ibutamoren
- โขOptimal dosing strategies that might mitigate glucose metabolism effects have not been explored
Research Overview#
Ibutamoren (MK-677) has been evaluated in several clinical trials, primarily sponsored by Merck & Co. during the late 1990s and 2000s. The evidence base includes phase 1 dose-finding studies, a landmark 2-year body composition trial in healthy elderly adults, and two hip fracture recovery trials. The overall evidence level is classified as moderate: while the trials were well-designed randomized controlled studies, the sample sizes were small, the hip fracture program was terminated early, and no phase 3 trials were ever initiated.
Key Clinical Studies#
Nass et al. (2008) - Body Composition in Healthy Elderly#
The most comprehensive published trial of MK-677 was conducted by Nass and colleagues (PMID 18981485), a 2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial involving 65 healthy adults aged 60 to 81 years.
Participants received MK-677 25 mg or placebo once daily, with fat-free mass and abdominal visceral fat as primary endpoints at 12 months. The study enrolled three groups: men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy.
Key results:
- Fat-free mass increased by 1.1 kg in the MK-677 group versus a decrease of 0.5 kg with placebo (P<0.001; between-group difference of 1.6 kg)
- GH secretion was enhanced by approximately 97% compared to baseline
- IGF-1 levels rose to ranges typical of healthy young adults
- No significant changes in total fat mass or visceral adipose tissue were observed
- Fasting blood glucose increased by approximately 0.3 mmol/L
- Insulin sensitivity declined modestly
The study demonstrated that MK-677 could sustainably restore the GH-IGF-1 axis in older adults but raised concerns about glucose metabolism effects.
Adunsky et al. (2011) - Hip Fracture Recovery#
This phase 2b trial (PMID 21067829) randomized 123 elderly patients recovering from hip fracture surgery to MK-677 25 mg or placebo daily for a planned 24 weeks. The trial was terminated early because of a higher rate of congestive heart failure in the ibutamoren group: 4 patients (6.5%) in the MK-677 group versus 1 patient (1.7%) in the placebo group developed CHF.
This safety signal effectively ended clinical development of MK-677 for elderly populations, the primary target demographic. The mechanism of CHF induction is thought to involve GH-mediated fluid retention in patients with underlying cardiac vulnerability.
Bach et al. (2004) - Earlier Hip Fracture Study#
An earlier, smaller trial by Bach and colleagues (PMID 15066065) evaluated MK-677 in hip fracture patients and suggested improvements in some muscle strength and functional performance measures. This trial did not identify CHF signals, but the subsequent larger Adunsky trial raised the safety concern that had not been detected in the smaller study.
Murphy et al. (1998) - Catabolic State Reversal#
Murphy and colleagues demonstrated that MK-677 25 mg daily could reverse diet-induced nitrogen wasting in healthy calorie-restricted volunteers, suggesting potential utility in catabolic states. This short-term study established the biological activity of oral MK-677 for GH axis stimulation.
GH and IGF-1 Effects Across Trials#
Across all published trials, MK-677 consistently demonstrated:
- Robust GH secretory pulse amplification (50-97% increase depending on population)
- Sustained IGF-1 elevation to youthful ranges
- Preservation of physiological pulsatile GH secretion patterns
- Maintained efficacy over extended treatment periods (up to 2 years)
Evidence Quality Assessment#
| Evidence Criterion | Assessment | Details |
|---|---|---|
| Study design | RCTs | Double-blind, placebo-controlled |
| Sample sizes | Small (n=65-123) | Insufficient for rare safety events |
| Consistency | Moderate | GH/IGF-1 effects consistent; safety variable |
| Active comparator | None | No head-to-head trials vs other GH therapies |
| Regulatory status | Never approved | Development effectively discontinued |
| Long-term data | Up to 2 years | Nass et al. body composition trial |
| Safety database | Limited | CHF signal identified in one trial |
Key Research Gaps#
-
Cardiovascular safety: The CHF signal from the Adunsky trial was identified in a small, high-risk population. Whether this risk extends to younger or healthier populations remains unknown.
-
Functional outcomes: No completed trial has demonstrated that MK-677-induced increases in fat-free mass translate to improved physical function, fall prevention, or quality of life.
-
Cancer risk: Elevated IGF-1 has been epidemiologically associated with increased risk of certain cancers. The long-term oncologic safety of sustained IGF-1 elevation with MK-677 has not been studied.
-
Glucose metabolism: Strategies to mitigate the insulin resistance and hyperglycemia observed with MK-677 have not been explored in clinical trials.
-
Combination approaches: The potential for combining MK-677 with GHRH analogs, exercise interventions, or insulin sensitizers has not been systematically evaluated.
Related Reading#
Frequently Asked Questions About Ibutamoren (MK-677)
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.